MedPath

benzonatate

Benzonatate Capsules, USP 200 mg

Approved
Approval ID

55c4ae18-3e37-4caf-9fdb-9d307970b5f9

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 8, 2023

Manufacturers
FDA

QPharma Inc

DUNS: 030620888

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

benzonatate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code42708-082
Application NumberANDA040749
Product Classification
M
Marketing Category
C73584
G
Generic Name
benzonatate
Product Specifications
Route of AdministrationORAL
Effective DateDecember 8, 2023
FDA Product Classification

INGREDIENTS (8)

GELATINInactive
Code: 2G86QN327L
Classification: IACT
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
PROPYLPARABENInactive
Code: Z8IX2SC1OH
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
METHYLPARABENInactive
Code: A2I8C7HI9T
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
BENZONATATEActive
Quantity: 200 mg in 1 1
Code: 5P4DHS6ENR
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

benzonatate - FDA Drug Approval Details